Home / Compare / CagriSema vs Tirzepatide

CagriSema vs Tirzepatide

CagriSema vs Tirzepatide: how they work, doses used, FDA status and trial weight loss (20.4% vs 20.9%), with sources.

CagriSemaTirzepatide
Works onAmylin (cagrilintide) + GLP-1 (semaglutide)GIP + GLP-1 (dual agonist)
How it is takenInjection, once weeklyInjection, once weekly (Mounjaro, Zepbound)
US statusNot approved (FDA decision expected late 2026)FDA-approved (2022 diabetes, 2023 weight)
Highest dose2.4 mg + 2.4 mg weekly (trial)15 mg weekly (label)
Key trialREDEFINE 1 (phase 3)SURMOUNT-1 (phase 3)
Average weight loss20.4% at 68 weeks (2.4 mg + 2.4 mg weekly)20.9% at 72 weeks (15 mg weekly)
Placebo in that trial3.0%3.1%
Not a head-to-head comparison. The weight-loss numbers come from separate trials with different people, doses and lengths. A direct trial is the only way to know which works better.

How they differ

CagriSema works on amylin (cagrilintide) + glp-1 (semaglutide); Tirzepatide works on gip + glp-1 (dual agonist). CagriSema is taken as: injection, once weekly.Tirzepatide is taken as: injection, once weekly (mounjaro, zepbound).

Dose schedules and warnings: CagriSema dosage chart ยท Tirzepatide dosage chart.

Questions

Is cagrisema stronger than tirzepatide?
No trial has compared them directly. In separate trials, CagriSema averaged 20.4% weight loss (REDEFINE 1 (phase 3), 68 weeks) and Tirzepatide 20.9% (SURMOUNT-1 (phase 3), 72 weeks). Different trials enroll different people over different lengths of time, so the numbers are not a fair head-to-head comparison.
Is cagrisema FDA-approved?
Not approved (FDA decision expected late 2026).
Is tirzepatide FDA-approved?
FDA-approved (2022 diabetes, 2023 weight).

Sources

  1. Garvey et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). NEJM 2025
  2. Jastreboff et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM 2022

Last checked 2026-11-16. How we pick and check sources: methodology.